Michael Ryskin

Stock Analyst at B of A Securities

(1.41)
# 3,591
Out of 5,149 analysts
41
Total ratings
50%
Success rate
-2.67%
Average return

Stocks Rated by Michael Ryskin

Recursion Pharmaceuticals
Feb 26, 2026
Maintains: Neutral
Price Target: $7$6
Current: $3.54
Upside: +69.49%
Zoetis
Feb 13, 2026
Maintains: Neutral
Price Target: $135$140
Current: $125.93
Upside: +11.17%
Schrödinger
Dec 15, 2025
Upgrades: Buy
Price Target: $24
Current: $12.50
Upside: +92.00%
Revvity
Sep 22, 2025
Maintains: Buy
Price Target: $110$99
Current: $95.95
Upside: +3.18%
Tempus AI
Jun 25, 2025
Maintains: Neutral
Price Target: $68$70
Current: $51.40
Upside: +36.19%
IDEXX Laboratories
Apr 21, 2025
Maintains: Neutral
Price Target: $535$475
Current: $635.54
Upside: -25.26%
Maravai LifeSciences Holdings
Mar 3, 2025
Maintains: Buy
Price Target: $9$8
Current: $3.69
Upside: +116.80%
Align Technology
Dec 13, 2024
Maintains: Underperform
Price Target: $200$206
Current: $182.64
Upside: +12.79%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28$40
Current: $93.30
Upside: -57.13%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10$9.5
Current: $0.88
Upside: +978.81%
Maintains: Buy
Price Target: $27$24
Current: $7.24
Upside: +231.49%
Maintains: Buy
Price Target: $27$24
Current: $8.78
Upside: +173.35%
Downgrades: Underperform
Price Target: $17$10
Current: $2.57
Upside: +289.11%